Krystal Biotech (KRYS) Financials

$125.61 +2.25 (+1.82%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$126.38 +0.78 (+0.62%)

As of 05/29/2025 05:24 PM Eastern

Annual Income Statements for Krystal Biotech

This table shows Krystal Biotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Net Income / (Loss) Attributable to Common Shareholders	89	11	-140	-70	-32	-19	-11	-7.92	-1.15
Consolidated Net Income / (Loss)	89	11	-140	-70	-32	-19	-11	-7.92	-1.15
Net Income / (Loss) Continuing Operations	89	11	-140	-70	-32	-19	-11	-7.92	-1.15
Total Pre-Tax Income	95	13	-140	-70	-32	-19	-11	-7.92	-1.15
Total Operating Income	66	-110	-145	-68	-33	-22	-12	-4.77	-1.14
Total Gross Profit	270	48	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue	291	51	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Revenue	291	51	0.00	0.00	-	-	-	-	-
Total Cost of Revenue	20	3.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cost of Revenue	20	3.09	-	0.00	-	-	-	-	-
Total Operating Expenses	205	157	145	68	33	22	12	4.77	1.14
Selling, General & Admin Expense	114	98	78	40	15	6.47	4.16	1.56	0.40
Research & Development Expense	54	46	42	28	18	16	7.76	3.21	0.74
Other Special Charges / (Income)	38	13	25	0.00	0.00	-	-	-	-
Total Other Income / (Expense), net	30	123	5.22	-1.30	0.83	2.99	1.03	-3.15	-0.01
Interest & Investment Income	30	23	5.22	0.20	-	-	-	-	-
Other Income / (Expense), net	0.00	100	0.00	0.00	0.83	-	1.03	-3.15	-0.01
Income Tax Expense	6.20	1.97	0.00	0.00	-	-	-	-	-
Basic Earnings per Share	$3.12	$0.40	($5.49)	($3.13)	($1.71)	($1.20)	($0.97)	($1.48)	($1.31)
Weighted Average Basic Shares Outstanding	28.59M	27.15M	25.49M	22.20M	18.79M	15.90M	11.20M	10.31M	877.49K
Diluted Earnings per Share	$3.00	$0.39	($5.49)	($3.13)	($1.71)	($1.20)	($0.97)	($1.48)	($1.31)
Weighted Average Diluted Shares Outstanding	29.74M	27.75M	25.49M	22.20M	18.79M	15.90M	11.20M	10.31M	877.49K
Weighted Average Basic & Diluted Shares Outstanding	28.81M	28.29M	-	25.76M	18.79M	15.90M	11.20M	5.36M	877.49K

This table shows Krystal Biotech's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	36	45	27	16	0.93	8.69	81	-33	-45	-32	-30
Consolidated Net Income / (Loss)	36	45	27	16	0.93	8.69	81	-33	-45	-32	-30
Net Income / (Loss) Continuing Operations	36	45	27	16	0.93	8.69	81	-33	-45	-32	-30
Total Pre-Tax Income	44	49	30	16	0.93	11	81	-33	-45	-32	-30
Total Operating Income	36	41	22	8.57	-6.68	3.14	-26	-38	-49	-35	-31
Total Gross Profit	83	86	77	64	43	39	8.56	0.00	0.00	-	0.00
Total Revenue	88	91	84	70	45	42	8.56	0.00	0.00	-	0.00
Operating Revenue	88	91	84	70	45	42	8.56	0.00	0.00	-	0.00
Total Cost of Revenue	5.03	4.95	6.68	6.01	2.42	3.09	0.00	0.00	0.00	-	0.00
Operating Cost of Revenue	5.03	4.95	6.68	6.01	2.42	-	-	0.00	0.00	-	0.00
Total Operating Expenses	47	45	55	56	50	36	34	38	49	35	31
Selling, General & Admin Expense	33	31	29	28	26	25	24	26	24	24	20
Research & Development Expense	14	14	14	16	11	11	11	12	12	11	12
Other Special Charges / (Income)	0.00	-	13	13	13	-	0.00	0.00	13	-	0.00
Total Other Income / (Expense), net	7.42	7.23	7.34	7.48	7.62	7.52	107	4.84	3.53	2.98	1.60
Interest & Investment Income	7.42	-	7.34	-	-	-	6.74	4.84	-	-	1.60
Income Tax Expense	7.86	-	2.59	0.48	-	-	0.00	0.00	-	-	-
Basic Earnings per Share	$1.24	$1.60	$0.95	$0.54	$0.03	$0.53	$2.88	($1.25)	($1.76)	($1.23)	($1.17)
Weighted Average Basic Shares Outstanding	28.82M	28.59M	28.72M	28.60M	28.30M	27.15M	28.04M	26.66M	25.71M	25.49M	25.62M
Diluted Earnings per Share	$1.20	$1.53	$0.91	$0.53	$0.03	$0.61	$2.79	($1.25)	($1.76)	($1.23)	($1.17)
Weighted Average Diluted Shares Outstanding	29.87M	29.74M	29.90M	29.64M	29.29M	27.75M	28.89M	26.66M	25.71M	25.49M	25.62M
Weighted Average Basic & Diluted Shares Outstanding	28.90M	28.81M	28.76M	28.73M	28.56M	28.29M	28.21M	-	27.99M	0.00	25.75M

This table details how cash moves in and out of Krystal Biotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Net Change in Cash & Equivalents	-13	196	-179	73	81	84	54	48	1.92
Net Cash From Operating Activities	123	-89	-101	-48	-26	-19	-9.45	-3.89	-1.31
Net Cash From Continuing Operating Activities	123	-89	-101	-48	-26	-19	-9.45	-3.89	-1.31
Net Income / (Loss) Continuing Operations	89	11	-140	-70	-32	-19	-11	-7.92	-1.15
Consolidated Net Income / (Loss)	89	11	-140	-70	-32	-19	-11	-7.92	-1.15
Depreciation Expense	5.97	5.01	2.64	1.85	1.85	1.09	0.14	0.02	0.00
Amortization Expense	0.75	-1.28	0.74	0.92	-	-	-	-	-
Non-Cash Adjustments To Reconcile Net Income	73	-65	33	17	3.31	1.31	0.79	3.51	0.04
Changes in Operating Assets and Liabilities, net	-45	-38	2.66	2.05	0.93	-2.00	0.51	0.50	-0.20
Net Cash From Investing Activities	-163	83	-114	-227	-11	-4.99	-10	-0.21	-0.02
Net Cash From Continuing Investing Activities	-163	83	-114	-227	-11	-4.99	-10	-0.21	-0.02
Purchase of Property, Plant & Equipment	-4.24	-12	-53	-68	-15	-6.40	-2.23	-0.21	-0.02
Purchase of Investments	-458	-509	-319	-190	-3.21	-9.09	-8.09	-	-
Divestitures	0.00	100	0.00	0.00	-	-	-	-	-
Sale and/or Maturity of Investments	299	503	258	32	6.87	11	-	-	-
Net Cash From Financing Activities	27	203	35	348	118	108	74	52	3.25
Net Cash From Continuing Financing Activities	27	203	35	348	118	108	74	52	3.25
Issuance of Common Equity	0.00	160	29	356	118	108	74	42	0.10
Other Financing Activities, net	27	43	6.36	-7.96	0.00	-	-	-	-
Effect of Exchange Rate Changes	-0.46	-0.16	-0.04	0.00	0.00	-	-	-	-
Cash Income Taxes Paid	5.67	0.00	0.00	-	-	-	-	-	-

This table details how cash moves in and out of Krystal Biotech's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-36	-29	28	-13	0.68	-15	97	135	-21	-25	-32
Net Cash From Operating Activities	31	53	59	-4.17	16	-7.23	-21	-34	-26	-22	-20
Net Cash From Continuing Operating Activities	31	53	59	-4.17	16	-7.23	-21	-34	-26	-23	-20
Net Income / (Loss) Continuing Operations	36	45	27	16	0.93	8.69	81	-33	-45	-32	-30
Consolidated Net Income / (Loss)	36	45	27	16	0.93	8.69	81	-33	-45	-32	-30
Depreciation Expense	1.41	1.36	1.34	1.84	1.43	1.52	1.14	1.26	1.09	-0.32	0.98
Amortization Expense	0.22	0.19	0.19	0.19	0.18	-1.95	0.23	0.22	0.22	-	-
Non-Cash Adjustments To Reconcile Net Income	-20	12	18	24	20	10	-94	-3.19	22	9.24	8.84
Changes in Operating Assets and Liabilities, net	13	-5.73	13	-45	-6.44	-26	-9.62	0.73	-3.69	-0.58	0.33
Net Cash From Investing Activities	-55	-84	-34	-19	-26	-10	105	-16	3.56	-5.21	-15
Net Cash From Continuing Investing Activities	-55	-84	-34	-19	-26	-10	105	-16	3.56	-5.21	-15
Purchase of Property, Plant & Equipment	-6.20	-0.80	-1.05	-1.13	-1.26	-1.85	-1.78	-2.79	-5.38	-5.22	-14
Purchase of Investments	-138	-143	-113	-113	-88	-83	-106	-174	-146	-104	-67
Sale of Property, Plant & Equipment	0.44	-	-	-	-	-	-	-	-	-	-
Sale and/or Maturity of Investments	89	60	79	95	64	75	113	161	155	104	67
Net Cash From Financing Activities	-12	2.43	3.37	11	11	2.62	13	185	1.47	3.07	2.12
Net Cash From Continuing Financing Activities	-12	2.43	3.37	11	11	2.62	13	185	1.47	3.07	2.12
Other Financing Activities, net	-12	2.43	3.37	11	11	2.61	14	25	1.47	7.01	-
Effect of Exchange Rate Changes	0.17	-0.59	0.29	-0.34	0.19	-0.14	0.01	-	-	-0.04	-
Cash Income Taxes Paid	0.40	0.52	3.15	-	-	-	-	-	-	-	-

This table presents Krystal Biotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2022	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Total Assets	1,056	818	558	558	311	209	116	50	2.18
Total Current Assets	742	588	384	384	275	196	113	50	2.17
Cash & Equivalents	345	358	162	162	268	188	104	50	1.92
Short-Term Investments	253	174	217	217	2.99	6.17	8.09	0.00	-
Accounts Receivable	105	42	0.00	-	-	-	-	-	-
Inventories, net	27	6.99	0.00	-	-	-	-	-	-
Prepaid Expenses	13	6.71	4.61	4.61	3.80	2.20	0.89	0.32	0.25
Plant, Property, & Equipment, net	155	161	162	162	31	8.48	3.01	0.20	0.01
Total Noncurrent Assets	159	69	13	13	4.91	4.67	0.45	0.00	0.00
Long-Term Investments	152	62	4.62	4.62	0.00	0.50	-	-	-
Other Noncurrent Operating Assets	6.51	7.29	8.37	8.37	4.91	4.17	0.45	-	-
Total Liabilities & Shareholders' Equity	1,056	818	558	558	311	209	116	50	2.18
Total Liabilities	109	40	36	36	19	6.11	2.89	0.64	1.89
Total Current Liabilities	102	33	29	29	15	3.33	2.60	0.64	0.04
Accounts Payable	64	26	27	27	2.11	1.02	2.60	0.64	0.04
Accrued Expenses	37	5.98	-	-	5.11	1.83	-	-	-
Other Current Liabilities	1.22	1.47	1.56	1.56	8.24	0.48	-	-	-
Total Noncurrent Liabilities	7.46	6.62	7.37	7.37	3.31	2.78	0.29	0.00	1.85
Other Noncurrent Operating Liabilities	7.46	6.62	7.37	7.37	3.31	2.78	0.29	0.00	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	946	779	522	522	292	203	113	49	0.29
Total Preferred & Common Equity	946	779	522	522	292	203	113	49	0.29
Total Common Equity	946	779	522	522	292	203	113	49	-1.12
Common Stock	1,127	1,048	804	804	363	242	133	59	0.03
Retained Earnings	-181	-270	-281	-281	-71	-39	-20	-9.07	-1.15
Accumulated Other Comprehensive Income / (Loss)	-0.19	0.64	-0.73	-0.73	0.01	0.01	0.00	0.00	-

This table presents Krystal Biotech's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	12/31/2022
Total Assets	1,074	982	918	853	790	684	558
Total Current Assets	767	713	683	602	582	484	384
Cash & Equivalents	309	374	346	359	373	276	162
Short-Term Investments	308	214	214	179	189	202	217
Accounts Receivable	103	97	103	46	9.32	-	-
Inventories, net	30	19	12	11	5.28	-	-
Prepaid Expenses	17	8.96	7.75	6.49	5.47	6.49	4.61
Plant, Property, & Equipment, net	151	157	159	160	164	164	162
Total Noncurrent Assets	157	113	76	91	44	36	13
Long-Term Investments	148	106	69	84	37	28	4.62
Other Noncurrent Operating Assets	8.08	6.67	6.79	7.04	7.65	7.88	8.37
Total Liabilities & Shareholders' Equity	1,074	982	918	853	790	684	558
Total Liabilities	90	96	79	54	34	31	36
Total Current Liabilities	79	90	72	48	28	24	29
Accounts Payable	31	59	49	35	26	22	27
Accrued Expenses	47	30	22	11	-	-	-
Other Current Liabilities	1.36	1.29	1.36	1.43	1.50	1.53	1.56
Total Noncurrent Liabilities	10	6.95	6.91	6.47	6.82	7.01	7.37
Other Noncurrent Operating Liabilities	10	6.95	6.91	6.47	6.82	7.01	7.37
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	985	886	839	799	756	653	522
Total Preferred & Common Equity	985	886	839	799	756	653	522
Total Common Equity	985	886	839	799	756	653	522
Common Stock	1,129	1,110	1,093	1,068	1,035	1,013	804
Retained Earnings	-145	-226	-253	-269	-279	-359	-281
Accumulated Other Comprehensive Income / (Loss)	0.39	1.51	-0.63	-0.30	-0.38	-0.24	-0.73

This table displays calculated financial ratios and metrics derived from Krystal Biotech's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	473.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	1,307.02%	95.77%	-116.49%	-116.08%	-44.42%	-95.30%	-36.10%	-587.89%	0.00%
EBIT Growth	775.39%	93.30%	-112.66%	-112.25%	-45.68%	-102.78%	-37.49%	-588.70%	0.00%
NOPAT Growth	166.04%	8.49%	-112.66%	-106.90%	-49.45%	-85.31%	-149.71%	-317.50%	0.00%
Net Income Growth	715.58%	107.81%	-101.20%	-116.28%	-68.52%	-75.30%	-37.49%	-588.70%	0.00%
EPS Growth	669.23%	107.10%	-75.40%	-83.04%	-42.50%	-23.71%	34.46%	-12.98%	0.00%
Operating Cash Flow Growth	238.98%	11.70%	-109.79%	-83.79%	-39.56%	-97.88%	-142.80%	-196.72%	0.00%
Free Cash Flow Firm Growth	135.37%	-36.84%	38.55%	-370.06%	-54.86%	-129.00%	-229.96%	0.00%	0.00%
Invested Capital Growth	6.63%	33.28%	0.00%	564.87%	138.46%	496.04%	1,352.14%	-154.17%	0.00%
Revenue Q/Q Growth	20.29%	492.55%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	124.97%	95.85%	-9.53%	-20.54%	-12.13%	-8.59%	-26.73%	0.00%	0.00%
EBIT Q/Q Growth	139.31%	93.41%	-9.75%	-20.17%	-11.94%	-9.62%	-26.99%	0.00%	0.00%
NOPAT Q/Q Growth	123.76%	10.00%	-9.75%	-20.17%	-14.84%	-9.62%	-29.56%	0.00%	0.00%
Net Income Q/Q Growth	70.24%	136.67%	-7.90%	-19.65%	-18.52%	-9.46%	-26.99%	0.00%	0.00%
EPS Q/Q Growth	44.23%	126.90%	-5.37%	-15.07%	-17.12%	-0.84%	-76.36%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	94.84%	14.53%	-1.44%	-36.72%	-4.09%	-22.90%	-17.27%	-48.25%	0.00%
Free Cash Flow Firm Q/Q Growth	817.93%	-13.78%	45.10%	-135.21%	-13.40%	-22.56%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	2.67%	17.27%	0.00%	201.56%	35.60%	96.76%	73,350.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	93.09%	93.90%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	24.92%	-11.83%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	22.61%	-216.43%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	22.61%	-19.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	30.69%	21.56%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	93.50%	84.76%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	145.15%	-132.59%	96.40%	101.90%	100.00%	86.45%	100.00%	100.00%	100.00%
Effective Tax Rate	6.50%	15.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	32.22%	-57.60%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	28.09%	-78.86%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-21.89%	59.28%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	10.34%	1.68%	-26.80%	-17.09%	-13.00%	-12.08%	-13.39%	-31.83%	-397.92%
Cash Return on Invested Capital (CROIC)	25.80%	-86.13%	-73.42%	-207.72%	-238.14%	-445.69%	-677.35%	0.00%	0.00%
Operating Return on Assets (OROA)	7.01%	-1.41%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	9.51%	1.59%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	10.34%	1.68%	-26.80%	-17.09%	-13.00%	-12.08%	-13.39%	-30.93%	1,538.00%
Return on Equity Simple (ROE_SIMPLE)	9.42%	1.40%	-26.80%	-13.32%	-11.01%	-9.41%	-9.62%	-16.01%	-397.92%
Net Operating Profit after Tax (NOPAT)	61	-93	-102	-48	-23	-15	-8.34	-3.34	-0.80
NOPAT Margin	21.14%	-183.45%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	4.13%	21.26%	-9.99%	-6.65%	-3.90%	-2.37%	-3.16%	-18.44%	-479.32%
Return On Investment Capital (ROIC_SIMPLE)	6.49%	-11.95%	-19.46%	-	-	-	-	-	-
Cost of Revenue to Revenue	6.91%	6.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	39.13%	194.09%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	18.44%	91.58%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	70.48%	310.33%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	66	-9.73	-145	-68	-32	-22	-11	-7.92	-1.15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	72	-6.00	-142	-66	-30	-21	-11	-7.90	-1.15
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.76	4.49	3.91	2.98	4.05	4.72	2.65	2.18	0.00
Price to Tangible Book Value (P/TBV)	4.76	4.49	3.91	2.98	4.05	4.72	2.65	2.18	0.00
Price to Revenue (P/Rev)	15.51	69.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	50.53	320.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.98%	0.31%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	19.09	15.75	11.96	8.46	43.76	87.54	128.38	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	12.93	57.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	51.87	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	57.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	61.15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	30.43	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	76.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.38
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.38
Financial Leverage	-0.78	-0.75	-0.73	-0.80	-0.94	-0.97	-0.99	-1.00	-0.25
Leverage Ratio	1.09	1.06	1.07	1.07	1.05	1.03	1.02	1.05	7.55
Compound Leverage Factor	1.58	-1.40	1.03	1.09	1.05	0.89	1.02	1.05	7.55
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	86.44%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	86.44%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	65.95%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-52.39%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.61
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.61
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.30
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.30
Altman Z-Score	25.67	53.24	32.99	25.42	38.16	94.64	62.84	101.37	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.83%	486.51%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	7.28	17.76	13.30	13.30	17.80	58.88	43.39	77.99	50.44
Quick Ratio	6.89	17.35	13.14	13.14	17.56	58.22	43.05	77.49	44.72
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	49	-139	-102	-165	-35	-23	-9.92	-3.01	0.00
Operating Cash Flow to CapEx	2,912.22%	-752.64%	-189.83%	-70.15%	-175.73%	-292.08%	-422.78%	-1,852.38%	-8,740.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	-110.86	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	-32.13	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	-77.93	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.31	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	3.96	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	1.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.84	0.31	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.45	0.12	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	92.21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	304.69	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	815.27	3,122.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	-418.36	-3,122.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	197	185	138	138	21	8.73	1.47	-0.12	0.22
Invested Capital Turnover	1.52	0.31	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	12	46	0.00	118	12	7.27	1.58	-0.33	0.00
Enterprise Value (EV)	3,756	2,905	1,656	1,172	911	764	188	58	0.00
Market Capitalization	4,506	3,499	2,040	1,556	1,182	959	300	108	0.00
Book Value per Share	$32.91	$27.61	$20.28	$23.48	$14.82	$11.72	$7.85	$4.83	($1.27)
Tangible Book Value per Share	$32.91	$27.61	$20.28	$23.48	$14.82	$11.72	$7.85	$4.83	($1.27)
Total Capital	946	779	522	522	292	203	113	49	2.13
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.84
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.84
Net Debt	-750	-594	-384	-384	-271	-194	-112	-50	-0.08
Capital Expenditures (CapEx)	4.24	12	53	68	15	6.40	2.23	0.21	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	43	23	-24	-24	-12	-1.13	-1.71	-0.32	0.20
Debt-free Net Working Capital (DFNWC)	640	555	355	355	260	193	110	49	2.13
Net Working Capital (NWC)	640	555	355	355	260	193	110	49	2.13
Net Nonoperating Expense (NNE)	-28	-104	38	22	9.07	3.63	2.55	4.58	0.35
Net Nonoperating Obligations (NNO)	-750	-594	-384	-384	-271	-194	-112	-50	-0.07
Total Depreciation and Amortization (D&A)	6.71	3.73	3.39	2.77	1.85	1.09	0.14	0.02	0.00
Debt-free, Cash-free Net Working Capital to Revenue	14.64%	44.65%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	220.32%	1,094.33%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	220.32%	1,094.33%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.12	$0.40	$0.00	$0.00	($1.71)	($1.20)	($0.97)	($1.48)	($1.31)
Adjusted Weighted Average Basic Shares Outstanding	28.59M	27.15M	0.00	0.00	22.19M	17.36M	11.20M	10.31M	877.49K
Adjusted Diluted Earnings per Share	$3.00	$0.39	$0.00	$0.00	($1.71)	($1.20)	($0.97)	($1.48)	($1.31)
Adjusted Weighted Average Diluted Shares Outstanding	29.74M	27.75M	0.00	0.00	22.19M	17.36M	11.20M	10.31M	877.49K
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($1.71)	($1.20)	($0.97)	($1.48)	($1.31)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	28.81M	28.29M	0.00	0.00	18.79M	15.90M	11.20M	5.36M	877.49K
Normalized Net Operating Profit after Tax (NOPAT)	96	-82	-84	-48	-23	-15	-8.34	-3.34	-0.80
Normalized NOPAT Margin	33.21%	-162.55%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	32.82%	25.44%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	-45.76	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	-32.03	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	-91.56	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	-77.83	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Krystal Biotech's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	94.88%	116.26%	879.91%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	845.04%	926.93%	-68.21%	149.40%	105.35%	107.73%	347.32%	-34.79%	3.44%	-59.42%	-104.96%
EBIT Growth	641.25%	737.90%	-69.69%	142.17%	101.91%	109.02%	335.31%	-35.36%	2.79%	-58.93%	-100.94%
NOPAT Growth	543.62%	1,219.09%	178.80%	131.21%	80.44%	112.89%	-18.07%	-32.33%	2.79%	-58.93%	-100.94%
Net Income Growth	3,734.01%	423.23%	-66.34%	146.88%	102.06%	127.12%	370.51%	-18.15%	9.34%	-46.99%	-91.48%
EPS Growth	3,900.00%	150.82%	-67.38%	142.40%	101.70%	149.59%	338.46%	-13.64%	11.56%	-29.47%	-67.14%
Operating Cash Flow Growth	94.92%	830.68%	377.29%	87.81%	160.74%	67.61%	-7.81%	20.60%	-68.82%	-6.84%	-171.37%
Free Cash Flow Firm Growth	65.14%	167.87%	69.21%	-314.37%	63.80%	-76.40%	60.82%	184.42%	-13.87%	81.69%	-175.96%
Invested Capital Growth	23.94%	6.63%	21.80%	0.00%	20.25%	33.28%	13.65%	0.00%	82.65%	0.00%	201.56%
Revenue Q/Q Growth	-3.24%	8.71%	19.29%	55.32%	7.37%	392.55%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	35.82%	16.18%	32.64%	610.98%	-54.42%	-96.40%	306.10%	23.03%	-35.39%	-15.15%	-12.32%
EBIT Q/Q Growth	37.63%	17.17%	39.81%	1,621.57%	-70.29%	-95.76%	294.51%	22.07%	-40.42%	-10.55%	-11.89%
NOPAT Q/Q Growth	-28.34%	102.03%	146.43%	224.35%	-313.07%	112.07%	2.41%	22.07%	-40.42%	-10.55%	-9.38%
Net Income Q/Q Growth	-21.43%	67.33%	74.59%	1,570.39%	-89.28%	-89.24%	343.14%	26.68%	-41.32%	-7.38%	-6.20%
EPS Q/Q Growth	-21.57%	68.13%	71.70%	1,666.67%	-95.08%	-78.14%	323.20%	28.98%	-43.09%	-5.13%	-6.36%
Operating Cash Flow Q/Q Growth	-41.39%	-10.22%	1,512.12%	-126.23%	319.69%	65.93%	37.92%	-30.72%	-17.14%	-13.41%	54.28%
Free Cash Flow Firm Q/Q Growth	-143.64%	310.84%	93.15%	-452.78%	15.02%	4.35%	-147.71%	193.35%	-314.07%	78.75%	-2.79%
Invested Capital Q/Q Growth	11.49%	2.67%	-8.74%	18.65%	-4.08%	17.27%	0.00%	-100.00%	6.32%	0.00%	14.68%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	94.30%	94.57%	92.03%	91.45%	94.65%	92.66%	100.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	42.88%	30.55%	28.58%	25.70%	5.62%	6.43%	880.93%	0.00%	0.00%	0.00%	0.00%
Operating Margin	41.02%	45.40%	26.76%	12.19%	-14.77%	7.44%	-303.80%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	41.02%	28.84%	26.76%	22.83%	2.06%	7.44%	864.97%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	40.52%	49.90%	32.42%	22.15%	2.06%	20.63%	943.75%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	81.96%	93.56%	91.30%	97.03%	100.00%	81.56%	100.00%	100.00%	100.00%	100.81%	100.00%
Interest Burden Percent	120.51%	184.93%	132.70%	100.00%	100.00%	339.72%	109.11%	87.28%	92.78%	91.44%	94.91%
Effective Tax Rate	18.04%	0.00%	8.70%	2.97%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	56.58%	69.19%	33.82%	18.72%	-8.74%	2.34%	-17.58%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	55.70%	68.58%	32.78%	16.41%	-10.09%	1.20%	-39.31%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-43.33%	-53.42%	-25.81%	-12.31%	7.84%	-0.90%	30.21%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	13.25%	15.77%	8.00%	6.42%	-0.90%	1.43%	12.63%	0.00%	-22.52%	-26.80%	-27.88%
Cash Return on Invested Capital (CROIC)	27.82%	25.80%	-3.93%	-219.98%	-60.08%	-86.13%	-82.66%	0.00%	-146.87%	-73.42%	-200.87%
Operating Return on Assets (OROA)	14.19%	8.94%	7.29%	4.14%	0.26%	0.55%	10.97%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	14.02%	15.47%	8.83%	4.01%	0.26%	1.52%	11.97%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	13.25%	15.77%	8.00%	6.42%	-0.90%	1.43%	12.63%	0.00%	-22.52%	-26.80%	-27.88%
Return on Equity Simple (ROE_SIMPLE)	12.59%	0.00%	5.91%	12.63%	7.15%	0.00%	-3.94%	0.00%	-20.72%	0.00%	-24.84%
Net Operating Profit after Tax (NOPAT)	30	41	20	8.31	-6.68	3.14	-26	-27	-34	-24	-22
NOPAT Margin	33.62%	45.40%	24.43%	11.83%	-14.77%	7.44%	-303.80%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	0.88%	0.61%	1.04%	2.31%	1.35%	1.14%	21.73%	0.00%	-2.28%	-2.01%	-2.10%
Return On Investment Capital (ROIC_SIMPLE)	3.01%	4.37%	-	-	-	0.40%	-	-	-	-4.66%	-
Cost of Revenue to Revenue	5.70%	5.43%	7.97%	8.55%	5.35%	7.34%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	37.11%	34.33%	34.25%	39.31%	57.59%	58.76%	276.96%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	16.17%	14.84%	16.12%	22.17%	24.21%	26.98%	124.23%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	53.27%	49.17%	65.27%	79.26%	109.43%	85.74%	401.19%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	36	26	22	16	0.93	3.14	74	-38	-49	-35	-31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	38	28	24	18	2.54	2.71	75	-37	-48	-35	-30
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.27	4.76	5.90	6.25	6.28	4.49	4.30	0.00	3.16	3.91	3.43
Price to Tangible Book Value (P/TBV)	5.27	4.76	5.90	6.25	6.28	4.49	4.30	0.00	3.16	3.91	3.43
Price to Revenue (P/Rev)	15.58	15.51	21.65	31.55	52.31	69.02	379.54	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	41.90	50.53	99.86	49.50	87.80	320.09	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.39%	1.98%	1.00%	2.02%	1.14%	0.31%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	20.19	19.09	23.67	21.98	24.84	15.75	16.84	0.00	10.58	11.96	10.15
Enterprise Value to Revenue (EV/Rev)	13.28	12.93	18.78	27.77	45.82	57.30	309.57	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	38.41	51.87	140.92	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	40.79	57.17	165.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	45.42	61.15	165.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	31.97	30.43	71.60	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	80.33	76.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.78	-0.78	-0.79	-0.75	-0.78	-0.75	-0.77	0.00	-0.81	-0.73	-0.80
Leverage Ratio	1.08	1.09	1.08	1.09	1.06	1.06	1.06	0.00	1.08	1.07	1.09
Compound Leverage Factor	1.30	2.01	1.43	1.09	1.06	3.60	1.15	0.00	1.00	0.98	1.03
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	35.72	25.54	33.29	40.60	56.16	53.29	57.30	0.00	39.87	33.64	29.51
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.65	7.28	7.97	9.50	12.66	17.76	21.10	0.00	20.25	13.30	13.30
Quick Ratio	9.06	6.89	7.66	9.23	12.29	17.35	20.72	0.00	19.98	13.14	13.14
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-13	29	-14	-202	-36	-43	-45	94	-101	-24	-115
Operating Cash Flow to CapEx	536.82%	6,597.13%	5,626.86%	-368.52%	1,260.95%	-391.55%	-1,191.80%	-1,225.45%	-486.08%	-428.00%	-140.07%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.35	0.31	0.27	0.18	0.12	0.07	0.01	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	4.45	3.96	4.53	1.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	1.11	1.20	1.53	0.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	2.14	1.84	1.51	1.05	0.59	0.31	0.05	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.69	0.45	0.43	0.24	0.19	0.12	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	81.95	92.21	80.56	226.68	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	329.89	304.69	239.17	385.81	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	528.03	815.27	849.77	1,544.55	1,894.82	3,122.02	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	-116.19	-418.36	-530.04	-932.06	-1,894.82	-3,122.02	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	219	197	192	210	177	185	157	0.00	147	138	138
Invested Capital Turnover	1.68	1.52	1.38	1.58	0.59	0.31	0.06	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	42	12	34	210	30	46	19	-121	67	0.00	93
Enterprise Value (EV)	4,428	3,756	4,536	4,616	4,396	2,905	2,649	0.00	1,557	1,656	1,405
Market Capitalization	5,194	4,506	5,230	5,244	5,019	3,499	3,247	3,029	2,063	2,040	1,789
Book Value per Share	$34.18	$32.91	$30.83	$29.37	$28.25	$27.61	$27.00	$0.00	$25.35	$20.28	$20.35
Tangible Book Value per Share	$34.18	$32.91	$30.83	$29.37	$28.25	$27.61	$27.00	$0.00	$25.35	$20.28	$20.35
Total Capital	985	946	886	839	799	779	756	0.00	653	522	522
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-765	-750	-694	-629	-622	-594	-599	0.00	-506	-384	-384
Capital Expenditures (CapEx)	5.77	0.80	1.05	1.13	1.26	1.85	1.78	2.79	5.38	5.22	14
Debt-free, Cash-free Net Working Capital (DFCFNWC)	70	43	35	51	16	23	-7.52	0.00	-17	-24	-24
Debt-free Net Working Capital (DFNWC)	687	640	624	611	555	555	555	0.00	460	355	355
Net Working Capital (NWC)	687	640	624	611	555	555	555	0.00	460	355	355
Net Nonoperating Expense (NNE)	-6.08	-4.10	-6.70	-7.26	-7.62	-5.56	-107	6.58	11	7.71	7.83
Net Nonoperating Obligations (NNO)	-765	-750	-694	-629	-622	-594	-599	0.00	-506	-384	-384
Total Depreciation and Amortization (D&A)	1.63	1.56	1.53	2.02	1.61	-0.43	1.37	1.48	1.31	-0.32	0.98
Debt-free, Cash-free Net Working Capital to Revenue	21.13%	14.64%	14.62%	30.87%	17.09%	44.65%	-87.94%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	206.12%	220.32%	258.22%	367.51%	578.08%	1,094.33%	6,481.36%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	206.12%	220.32%	258.22%	367.51%	578.08%	1,094.33%	6,481.36%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.24	$1.60	$0.95	$0.54	$0.03	$0.53	$2.88	$0.00	$0.00	($1.23)	($1.17)
Adjusted Weighted Average Basic Shares Outstanding	28.82M	28.59M	28.72M	28.60M	28.30M	27.15M	28.04M	0.00	0.00	25.49M	25.62M
Adjusted Diluted Earnings per Share	$1.20	$1.53	$0.91	$0.53	$0.03	$0.61	$2.79	$0.00	$0.00	($1.23)	($1.17)
Adjusted Weighted Average Diluted Shares Outstanding	29.87M	29.74M	29.90M	29.64M	29.29M	27.75M	28.89M	0.00	0.00	25.49M	25.62M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	28.90M	28.81M	28.76M	28.73M	28.56M	28.29M	28.21M	0.00	0.00	0.00	25.75M
Normalized Net Operating Profit after Tax (NOPAT)	30	29	32	20	4.07	2.20	-18	-27	-25	-24	-22
Normalized NOPAT Margin	33.62%	31.78%	38.04%	29.08%	9.00%	5.21%	-212.66%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	49.44%	53.34%	35.51%	22.83%	2.06%	25.29%	943.75%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Krystal Biotech's Financials

When does Krystal Biotech's financial year end?

According to the most recent income statement we have on file, Krystal Biotech's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Krystal Biotech's net income changed over the last 8 years?

Krystal Biotech's net income appears to be on a downward trend, with a most recent value of $89.16 million in 2024, falling from -$1.15 million in 2016. The previous period was $10.93 million in 2023. Check out Krystal Biotech's forecast to explore projected trends and price targets.

What is Krystal Biotech's operating income?

Krystal Biotech's total operating income in 2024 was $65.70 million, based on the following breakdown:

Total Gross Profit: $270.45 million
Total Operating Expenses: $204.76 million

How has Krystal Biotech revenue changed over the last 8 years?

Over the last 8 years, Krystal Biotech's total revenue changed from $0.00 in 2016 to $290.52 million in 2024, a change of 29,051,500,000.0%.

How much debt does Krystal Biotech have?

Krystal Biotech's total liabilities were at $109.46 million at the end of 2024, a 175.6% increase from 2023, and a 5,682.3% increase since 2016.

How much cash does Krystal Biotech have?

In the past 8 years, Krystal Biotech's cash and equivalents has ranged from $1.92 million in 2016 to $358.33 million in 2023, and is currently $344.87 million as of their latest financial filing in 2024.

How has Krystal Biotech's book value per share changed over the last 8 years?

Over the last 8 years, Krystal Biotech's book value per share changed from -1.27 in 2016 to 32.91 in 2024, a change of -2,685.1%.

Related Companies

This page (NASDAQ:KRYS) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Krystal Biotech (KRYS) Financials

Frequently Asked Questions About Krystal Biotech's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Krystal Biotech (KRYS) Financials

Annual Income Statements for Krystal Biotech

Quarterly Income Statements for Krystal Biotech

Annual Cash Flow Statements for Krystal Biotech

Quarterly Cash Flow Statements for Krystal Biotech

Annual Balance Sheets for Krystal Biotech

Quarterly Balance Sheets for Krystal Biotech

Annual Metrics And Ratios for Krystal Biotech

Quarterly Metrics And Ratios for Krystal Biotech

Frequently Asked Questions About Krystal Biotech's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools